Month: November 2022

On February 10, 2010, Kent, Perry; Nguyen, Truong published a patent.Related Products of 5709-67-1 The title of the patent was High temperature thermal cutoff device. And the patent contained the following:

The present disclosure provides high temperature thermal cutoff devices having a high-temperature thermal pellet with a transition temperature of greater than or equal to ∼240° and comprising at least one organic compound The pellet is disposed in a housing, which is sealed with a high-temperature seal that provides substantial sealing up to at least the transition temperature The high-temperature TCO also has a current interruption assembly, which establishes elec. continuity in a 1st operating condition corresponding to an operating temperature of less than said transition temperature and discontinues elec. continuity when the operating temperature exceeds the transition temperature Methods of making such high-temperature thermal cut off devices are also provided. The experimental process involved the reaction of 2-Nitro-1H-benzo[d]imidazole(cas: 5709-67-1).Related Products of 5709-67-1

The Article related to thermal cutoff device high temperature organic compound, tco, Electric Phenomena: Conductors, Semiconductors, Resistors, Contacts and other aspects.Related Products of 5709-67-1

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

On April 1, 2020, Hilton-Proctor, J. P.; Ilyichova, O.; Zheng, Z.; Jennings, I. G.; Johnstone, R. W.; Shortt, J.; Mountford, S. J.; Scanlon, M. J.; Thompson, P. E. published an article.Formula: C6H11N3 The title of the article was Substituted 1-methyl-4-phenylpyrrolidin-2-ones – Fragment-based design of N-methylpyrrolidone-derived bromodomain inhibitors. And the article contained the following:

The synthesis of a 4-Ph substituted analog – 1-methyl-4-phenylpyrrolidin-2-one – and the use of aryl substitution reactions as a divergent route for derivatives I (R = H, Br, Ph, 2-phenylethyl, etc.; R1 = 2-Br, 4-Ph, morpholine-4-sulfonyl, etc.) were described. Ultimately, this has led to structurally complex, chiral compounds (R/S)-II (R2 = H, Me; R3 = H, 3,4-dimethoxyphenyl; R4 = H, N,N-diethylsulfamoyl) with progressively improved affinity as inhibitors of bromodomain-containing protein 4. The experimental process involved the reaction of N-(3-Aminopropyl)-imidazole(cas: 5036-48-6).Formula: C6H11N3

The Article related to methyl phenylpyrrolidinone preparation bromodomain inhibitor, brd4, bromodomain, epigenetics, fragment-based drug design, k-ac, Heterocyclic Compounds (One Hetero Atom): Pyrroles and Pyrrolizines and other aspects.Formula: C6H11N3

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

On June 24, 2021, Machacek, Michelle; Altman, Michael D.; Huang, Chunhui; Reutershan, Michael H.; Sloman, David L.; Siliphaivanh, Phieng; Schneider, Sebastian E.; Yeung, Charles S.; Witter, David J.; Gibeau, Craig R.; Ye, Yingchun published a patent.Safety of 6-(Trifluoromethyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-2-carboxylic acid The title of the patent was Protein-arginine N-methyltransferase PRMT5 inhibitors for therapy. And the patent contained the following:

The present invention provides compounds and pharmaceutically acceptable salts, esters, and prodrugs thereof, which are PRMT5 inhibitors. These compounds can treat cancer, sickle cell, and hereditary persistence of fetal Hb mutations. The experimental process involved the reaction of 6-(Trifluoromethyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-2-carboxylic acid(cas: 1774893-22-9).Safety of 6-(Trifluoromethyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-2-carboxylic acid

The Article related to methyltransferase prmt5 inhibitor pharmaceutical, Pharmacology: Other (All Agents and Effects Not Otherwise Assignable) and other aspects.Safety of 6-(Trifluoromethyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-2-carboxylic acid

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

On January 15, 2013, Si, Yuhui; Sun, Gangchun; Li, Zhicheng; Li, Yaping published an article.HPLC of Formula: 73590-85-9 The title of the article was Synthesis and resolution of omeprazole. And the article contained the following:

Omeprazole was synthesized and resolved by chiral resolution agent to obtain the S-isomer (Esomeprazole). The resolving conditions were as follows: S-(-)-1, 1′-Binaphthyl-2, 2′-diol, racemic omeprazole and alkali (molar ratio 1:1.6:1.8) reacted in ethanol and water (3.7:1 in v:v) at room temperature for 12 h. The magnesium salt of Esomeprazole was obtained in a high yield (89%) and excellent enantioselectivity (97.95% ee). The experimental process involved the reaction of 5-Methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridyl)methyl]thio]benzimidazole(cas: 73590-85-9).HPLC of Formula: 73590-85-9

The Article related to esomeprazole omeprazole synthesis chiral resolution, Pharmacology: Other (All Agents and Effects Not Otherwise Assignable) and other aspects.HPLC of Formula: 73590-85-9

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

On January 25, 2021, Forrest, Michael D. published a patent.Related Products of 50743-01-6 The title of the patent was Therapeutic modifiers of the reverse mode of ATP synthase for treating diseases. And the patent contained the following:

Compounds that slow the ATP-hydrolyzing mode of ATP synthase are useful for treating various diseases and disorders including cancer, particularly cancers that utilize the Warburg effect. The experimental process involved the reaction of 5-Bromo-1H-imidazole-4-carbaldehyde(cas: 50743-01-6).Related Products of 50743-01-6

The Article related to atp synthase reverse mode modifier disease treatment, Pharmacology: Other (All Agents and Effects Not Otherwise Assignable) and other aspects.Related Products of 50743-01-6

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

On August 31, 2015, Liu, Xiao-ping; Xu, Hui-lan; Sun, Rui; Li, Xue; Hu, Bao-hua; Hu, Chun published an article.Synthetic Route of 73590-85-9 The title of the article was Synthesis and characterization of two impurities in esomeprazole, an antiulcerative drug. And the article contained the following:

Impurity control is a key factor for drug quality. Study for impurities is helpful to optimize the production process and improve the quality of drugs. Synthesis and characterization of two of impurities in esomeprazole, which used for treatment of acid-related diseases was described in this paper. The two impurities are known as 2-[(3,5-dimethyl-4-methoxy-2-pyridinyl)methylsulfinyl]-1H-benzimidazole (impurity 1) and (R)-5-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]-1H-benzimidazole (esomeprazole impurity F), whose structures are characterized with MS, IR, 1H-NMR and elemental analyses, and the purities of the two impurities are above 99% by HPLC anal. The two target compounds can be used as the reference substance of the impurities of esomeprazole. The experimental process involved the reaction of 5-Methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridyl)methyl]thio]benzimidazole(cas: 73590-85-9).Synthetic Route of 73590-85-9

The Article related to antiulcerative drug esomeprazole impurity acid disease, Pharmacology: Other (All Agents and Effects Not Otherwise Assignable) and other aspects.Synthetic Route of 73590-85-9

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

On November 5, 2020, Rosen, Yael; Dangoor, David; Fisher, Richard published a patent.HPLC of Formula: 65896-14-2 The title of the patent was Methods of treating pruritus by topically administering an α-2 adrenoreceptor agonist. And the patent contained the following:

The present disclosure related to methods of treating pruritus in a subject by topically administering an α-2 adrenoreceptor agonist to a subject. The experimental process involved the reaction of N-(2-Bromo-6-fluorophenyl)-4,5-dihydro-1H-imidazol-2-amine hydrochloride(cas: 65896-14-2).HPLC of Formula: 65896-14-2

The Article related to pruritus treatment topical alpha2 adrenoreceptor agonist, Pharmacology: Other (All Agents and Effects Not Otherwise Assignable) and other aspects.HPLC of Formula: 65896-14-2

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

On December 19, 2019, Aspnes, Gary Erik; Bagley, Scott W.; Conn, Edward L.; Curto, John M.; Edmonds, David James; Flanagan, Mark E.; Futatsugi, Kentaro; Griffith, David A.; Huard, Kim; Limberakis, Chris; Mathiowetz, Alan M.; Piotrowski, David W.; Ruggeri, Roger B. published a patent.Electric Literature of 1255717-13-5 The title of the patent was GLP-1 receptor agonists and uses thereof. And the patent contained the following:

Provided herein are 6-carboxylic acids of benzimidazoles and 4-aza-, 5-aza-, and 7-aza- benzimidazoles as GLP-1R agonists, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof. The experimental process involved the reaction of (1-Ethyl-1H-imidazol-5-yl)methanamine dihydrochloride(cas: 1255717-13-5).Electric Literature of 1255717-13-5

The Article related to glp1 receptor agonist benzimidazole preparation cardiometabolic disease, Pharmacology: Effects Of Cardiovascular, Hematologic, and Renal Drugs and other aspects.Electric Literature of 1255717-13-5

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

On January 31, 2007, Buhl, Rikke; Ersboell, Annette K.; Larsen, Nanna H.; Eriksen, Lis; Koch, Joergen published an article.Application In Synthesis of N-(2-Bromo-6-fluorophenyl)-4,5-dihydro-1H-imidazol-2-amine hydrochloride The title of the article was The effects of detomidine, romifidine or acepromazine on echocardiographic measurements and cardiac function in normal horses. And the article contained the following:

To evaluate by echo- and electrocardiog. the cardiac effects of sedation with detomidine hydrochloride, romifidine hydrochloride or acepromazine maleate in horses. An exptl. study using a crossover design without randomization. Animals Eight clin. normal Standardbred trotters. Echocardiog. examinations (two-dimensional, guided M-mode and color Doppler) were recorded on five different days. Heart rate (HR) and standard limb lead electrocardiograms were also obtained. Subsequently, horses were sedated with detomidine (0.01 mg kg-1), romifidine (0.04 mg kg-1) or acepromazine (0.1 mg kg-1) administered i.v. and all examinations repeated. Heart rate before treatment with the three drugs did not differ significantly (p = 0.98). Both detomidine and romifidine induced a significant decrease (p < 0.001) in HR during the first 25 min after sedation; while acepromazine had a varying effect on HR. For detomidine, there was a significant increase in LVIDd (left ventricular internal diameter in diastole; p = 0.034) and LVIDs (left ventricular internal diameter in systole; p < 0.001). In addition, a significant decrease was found in IVSs (the interventricular septum in systole; p < 0.001), LVFWs (the left ventricular free wall in systole; p = 0.002) and FS% (fractional shortening; p < 0.001). The frequency of pulmonary regurgitation was increased significantly (p < 0.001). Romifidine induced a significant increase in LVIDs (p < 0.001) and a significant decrease in IVSs (p < 0.001) and FS% (p = 0.002). Acepromazine had no significant effect upon any of the measured values. The results indicate that sedation of horses with detomidine and to a lesser extent romifidine at the doses given in this study has a significant effect on heart function, echocardiog. measurements of heart dimensions and the occurrence of valvular regurgitation. Although the clin. significance of these results may be minimal, the potential effects of sedative drugs should be taken into account when echocardiog. variables are interpreted in clin. cases. The experimental process involved the reaction of N-(2-Bromo-6-fluorophenyl)-4,5-dihydro-1H-imidazol-2-amine hydrochloride(cas: 65896-14-2).Application In Synthesis of N-(2-Bromo-6-fluorophenyl)-4,5-dihydro-1H-imidazol-2-amine hydrochloride

The Article related to horse heart rate electrocardiog echocardiog domosedan sedivet plegicil sedative, Pharmacology: Effects Of Cardiovascular, Hematologic, and Renal Drugs and other aspects.Application In Synthesis of N-(2-Bromo-6-fluorophenyl)-4,5-dihydro-1H-imidazol-2-amine hydrochloride

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

On July 31, 2014, Marzok, Mohamed A.; El-khodery, Sabry A.; Oheida, Aiman H. published an article.Category: imidazoles-derivatives The title of the article was Effect of intravenous administration of romifidine on intraocular pressure in clinically normal horses. And the article contained the following:

Objective : To evaluate the effect of i.v. administration of romifidine on the intraocular pressure (IOP) in horses. Animals studied : Twenty-four horses with no ocular abnormalities. Procedure : Horses were randomly assigned into two equal groups (treatment and control). All horses in the treatment group received an i.v. (IV) injection of romifidine (40 μg/kg). The horses in the control group were administrated an i.v. injection of 0.9% saline (0.4 mL/100 kg). In both groups, the IOP values were measured immediately (T0) pre-administration and at 5 (T5), 15 (T15), 30 (T30), 45 (T45), 60 (T60), 90 (T90), and 120 (T120) min after drug administration. Results : The pre-treatment values (T0) of IOP for right and left eyes were 24.25 ± 3.5 and 25.16 ± 3.4 mmHg, resp. A significant decrease in IOP values was observed in both right and left eyes of the horses in treatment group at T5, T15, T30, T45, T60, and T90 in comparison with the baseline values (P < 0.05). The lowest level of IOP in romifidine-treated groups was recorded at T45 for the right and left eyes (10.25 ± 2.3 and 11.25 ± 3.5 mmHg, resp.). Conclusion : Romifidine significantly decreased IOP in clin. normal horses and may be used safely for surgery or diagnostic ocular procedures in horses when specific control of IOP is required. The experimental process involved the reaction of N-(2-Bromo-6-fluorophenyl)-4,5-dihydro-1H-imidazol-2-amine hydrochloride(cas: 65896-14-2).Category: imidazoles-derivatives

The Article related to sedivet alpha2 adrenoceptor agonist intraocular pressure horse antiglaucoma, applanation tonometry, horse, intraocular pressure, romifidine, Pharmacology: Other (All Agents and Effects Not Otherwise Assignable) and other aspects.Category: imidazoles-derivatives

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem